(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s prostate cancer session included a presentation by Dr. Daniel George presenting data assessing real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC). ADT remains the backbone of therapy for mCSPC, however randomized trials have shown that adding docetaxel or novel hormonal therapy to androgen deprivation therapy (ADT) improves survival in mCSPC. The National Comprehensive Cancer Network treatment guidelines recommend ADT in combination with docetaxel or novel hormone therapy (abiraterone, apalutamide, and enzalutamide) for patients with mCSPC. Additionally, real-world data on treatment distribution and clinical outcomes in mCSPC after docetaxel and novel hormone therapy introduction are limited. This study using the Medicare database (Jan 2009–Dec 2018) aimed to evaluate real-world utilization of advanced therapies for men with mCSPC over time by metastatic site and age.